Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity

Related Experiment Video

Updated: Jun 24, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Juxiang Cao1, Jennifer Schulte, Alexander Knight

  • 1Department of Cell and Molecular Pharmacology and Experimental Therapeutics Medical Medical University of South Carolina, Charleston, SC 29425, USA.

The EMBO Journal
|April 17, 2009
PubMed

Insights

Peroxiredoxin1 (Prdx1) protects the tumor suppressor PTEN from oxidation. Loss of Prdx1 leads to PTEN inactivation and promotes Ras-induced breast cancer, revealing a new mechanism in tumorigenesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Reactive oxygen species (ROS) are implicated in cancer development, but mechanisms remain elusive.
  • Mice lacking peroxiredoxin1 (Prdx1) exhibit increased ROS and premature cancer, serving as a model for ROS-induced tumorigenesis.
  • Prdx1 deficiency exacerbates Ras-induced breast cancer susceptibility.

Purpose of the Study:

  • To investigate the role of Prdx1 in regulating oncogenic Ras effector pathways.
  • To elucidate the mechanism by which Prdx1 influences Akt activation and tumor suppression.

Main Methods:

  • Analysis of Akt activation in Prdx1-deficient fibroblasts and mammary epithelial cells.
  • Investigation of the interaction between Prdx1 and PTEN.
  • Assessment of Prdx1's role in Ras- or ErbB-2-induced transformation.

Main Results:

  • Prdx1 deficiency leads to hyperactive Akt signaling.
  • Prdx1 directly binds to PTEN, safeguarding its lipid phosphatase activity from oxidation-induced inactivation.
  • Prdx1's tumor-suppressive function against Ras and ErbB-2 is primarily mediated through PTEN.

Conclusions:

  • Prdx1 acts as a crucial safeguard for PTEN's tumor-suppressive function by preventing its oxidative inactivation.
  • This interaction highlights a novel mechanism linking ROS, Prdx1, PTEN, and Akt in cancer development.
  • Targeting the Prdx1-PTEN axis may offer therapeutic strategies for cancers driven by ROS and oncogenic signaling.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...